Your browser doesn't support javascript.
loading
Enhancing the Detection and Care of Heterozygous Familial Hypercholesterolemia in Primary Care: Cost-Effectiveness and Return on Investment.
Marquina, Clara; Morton, Jedidiah; Brett, Tom; Lloyd, Melanie; Radford, Jan; Heal, Clare; Hespe, Charlotte; Gill, Gerard; Sullivan, David; Zomer, Ella; Li, Ian; Pang, Jing; Watts, Gerald F; Ademi, Zanfina.
Affiliation
  • Marquina C; School of Public Health & Preventive Medicine (C.M., J.M., M.L., E.Z.), Monash University.
  • Morton J; Centre for Medicine Use & Safety, Faculty of Pharmacy & Pharmaceutical Sciences (C.M., J.M., M.L., Z.A.), Monash University.
  • Brett T; School of Public Health & Preventive Medicine (C.M., J.M., M.L., E.Z.), Monash University.
  • Lloyd M; Centre for Medicine Use & Safety, Faculty of Pharmacy & Pharmaceutical Sciences (C.M., J.M., M.L., Z.A.), Monash University.
  • Radford J; Baker Heart & Diabetes Institute, Melbourne (J.M.).
  • Heal C; General Practice & Primary Health Care Research, School of Medicine, The University of Notre Dame Australia, Fremantle, Western Australia (T.B.).
  • Hespe C; School of Public Health & Preventive Medicine (C.M., J.M., M.L., E.Z.), Monash University.
  • Gill G; Centre for Medicine Use & Safety, Faculty of Pharmacy & Pharmaceutical Sciences (C.M., J.M., M.L., Z.A.), Monash University.
  • Sullivan D; Launceston Clinical School, University of Tasmania, Tasmania (J.R.).
  • Zomer E; Mackay Clinical School, James Cook University, Queensland (C. Heal).
  • Li I; School of Medicine, The University of Notre Dame Australia, Sydney, New South Wales (C. Hespe).
  • Pang J; School of Medicine, Deakin University, Victoria (G.G.).
  • Watts GF; Department of Chemical Pathology, Royal Prince Alfred Hospital, NSW Health Pathology (D.S.).
  • Ademi Z; School of Public Health & Preventive Medicine (C.M., J.M., M.L., E.Z.), Monash University.
Circ Genom Precis Med ; 16(3): 267-274, 2023 06.
Article de En | MEDLINE | ID: mdl-37042242
ABSTRACT

BACKGROUND:

Heterozygous familial hypercholesterolemia (HeFH) is under-detected and undertreated. A general practitioner-led screening and care program for HeFH effectively identified and managed patients with HeFH. We evaluated the cost-effectiveness and the return on investment of an enhanced-care strategy for HeFH in primary care in Australia.

METHODS:

We developed a multistate Markov model to estimate the outcomes and costs of a general practitioner-led detection and management strategy for HeFH in primary care compared with the standard of care in Australia. The population comprised individuals aged 50 to 80 years, of which 44% had prior cardiovascular disease. Cardiovascular risk, HeFH prevalence, treatment effects, and acute and chronic health care costs were derived from published sources. The study involved screening for HeFH using a validated data-extraction tool (TARB-Ex), followed by a consultation to improve care. The detection rate of HeFH was 16%, and 74% of the patients achieved target LDL-C (low-density lipoprotein cholesterol). Quality-adjusted life years, health care costs, productivity losses, incremental cost-effectiveness ratio, and return on investment ratio were evaluated, outcomes discounted by 5% annually, adopting a health care and a societal perspective.

RESULTS:

Over the lifetime horizon, the model estimated a gain of 870 years of life lived and 1033 quality-adjusted life years when the general practitioner-led program was employed compared with standard of care. This resulted in an incremental cost-effectiveness ratio of AU$14 664/quality-adjusted life year gained from a health care perspective. From a societal perspective, this strategy, compared with standard of care was cost-saving, with a return on investment of AU$5.64 per dollar invested.

CONCLUSIONS:

An enhanced general practitioner-led model of care for HeFH is likely to be cost-effective.
Sujet(s)
Mots clés

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Hypercholestérolémie / Hyperlipoprotéinémie de type II Type d'étude: Diagnostic_studies / Health_economic_evaluation / Prognostic_studies / Risk_factors_studies Aspects: Patient_preference Limites: Humans Langue: En Journal: Circ Genom Precis Med Année: 2023 Type de document: Article

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Hypercholestérolémie / Hyperlipoprotéinémie de type II Type d'étude: Diagnostic_studies / Health_economic_evaluation / Prognostic_studies / Risk_factors_studies Aspects: Patient_preference Limites: Humans Langue: En Journal: Circ Genom Precis Med Année: 2023 Type de document: Article